Astellas Pharma Inc. (4503.T)
JPY 1521.5
(0.8%)
JPY 1521.5
(0.8%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 17.04 Billion JPY | -82.73% |
| 2022 | 98.71 Billion JPY | -20.45% |
| 2021 | 124.08 Billion JPY | 2.9% |
| 2020 | 120.58 Billion JPY | -38.29% |
| 2019 | 195.41 Billion JPY | -12.08% |
| 2018 | 222.26 Billion JPY | 34.97% |
| 2017 | 164.67 Billion JPY | -24.7% |
| 2016 | 218.7 Billion JPY | 12.91% |
| 2015 | 193.68 Billion JPY | 42.57% |
| 2014 | 135.85 Billion JPY | 49.5% |
| 2013 | 90.87 Billion JPY | 9.68% |
| 2012 | 82.85 Billion JPY | 5.91% |
| 2011 | 78.23 Billion JPY | 15.64% |
| 2010 | 67.65 Billion JPY | -44.67% |
| 2009 | 122.25 Billion JPY | -28.5% |
| 2008 | 170.98 Billion JPY | -3.64% |
| 2007 | 177.43 Billion JPY | 35.15% |
| 2006 | 131.28 Billion JPY | 26.65% |
| 2005 | 103.65 Billion JPY | 207.44% |
| 2004 | 33.71 Billion JPY | -43.86% |
| 2003 | 60.05 Billion JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 35.9 Billion JPY | -4.51% |
| 2024 Q1 | 37.6 Billion JPY | 213.0% |
| 2023 Q1 | 33.12 Billion JPY | 171.82% |
| 2023 Q2 | -1.45 Billion JPY | -104.4% |
| 2023 FY | 17.04 Billion JPY | -82.73% |
| 2023 Q3 | 14.51 Billion JPY | 1094.72% |
| 2023 Q4 | -33.27 Billion JPY | -329.3% |
| 2022 Q4 | -46.12 Billion JPY | -195.29% |
| 2022 Q2 | 71.62 Billion JPY | 188.66% |
| 2022 FY | 98.71 Billion JPY | -20.45% |
| 2022 Q1 | 24.81 Billion JPY | 395.06% |
| 2022 Q3 | 48.4 Billion JPY | -32.42% |
| 2021 Q1 | 30.68 Billion JPY | 348.92% |
| 2021 Q2 | 40.92 Billion JPY | 33.35% |
| 2021 Q4 | -8.4 Billion JPY | -113.81% |
| 2021 FY | 124.08 Billion JPY | 2.9% |
| 2021 Q3 | 60.88 Billion JPY | 48.78% |
| 2020 Q3 | 60.07 Billion JPY | 167.91% |
| 2020 FY | 120.58 Billion JPY | -38.29% |
| 2020 Q1 | 50.41 Billion JPY | 835.31% |
| 2020 Q2 | 22.42 Billion JPY | -55.52% |
| 2020 Q4 | -12.32 Billion JPY | -120.52% |
| 2019 Q3 | 61.49 Billion JPY | -12.16% |
| 2019 FY | 195.41 Billion JPY | -12.08% |
| 2019 Q1 | 58.51 Billion JPY | 90.43% |
| 2019 Q2 | 70 Billion JPY | 19.64% |
| 2019 Q4 | 5.39 Billion JPY | -91.23% |
| 2018 Q2 | 49.3 Billion JPY | -9.63% |
| 2018 Q3 | 87.66 Billion JPY | 77.8% |
| 2018 Q4 | 30.73 Billion JPY | -64.95% |
| 2018 FY | 222.26 Billion JPY | 34.97% |
| 2018 Q1 | 54.55 Billion JPY | 147.26% |
| 2017 Q2 | 39.64 Billion JPY | -6.64% |
| 2017 FY | 164.67 Billion JPY | -24.7% |
| 2017 Q4 | 22.06 Billion JPY | -63.53% |
| 2017 Q3 | 60.49 Billion JPY | 52.58% |
| 2017 Q1 | 42.46 Billion JPY | 6.43% |
| 2016 Q2 | 48.45 Billion JPY | -27.26% |
| 2016 Q4 | 39.9 Billion JPY | -37.4% |
| 2016 Q3 | 63.73 Billion JPY | 31.55% |
| 2016 Q1 | 66.61 Billion JPY | 128.6% |
| 2016 FY | 218.7 Billion JPY | 12.91% |
| 2015 Q2 | 58.31 Billion JPY | 30.68% |
| 2015 Q1 | 44.62 Billion JPY | 111.36% |
| 2015 FY | 193.68 Billion JPY | 42.57% |
| 2015 Q4 | 29.14 Billion JPY | -52.71% |
| 2015 Q3 | 61.61 Billion JPY | 5.66% |
| 2014 Q3 | 44.76 Billion JPY | 31.17% |
| 2014 Q2 | 34.12 Billion JPY | -4.85% |
| 2014 FY | 135.85 Billion JPY | 49.5% |
| 2014 Q1 | 35.86 Billion JPY | 281.09% |
| 2014 Q4 | 21.11 Billion JPY | -52.83% |
| 2013 FY | 90.87 Billion JPY | 9.68% |
| 2013 Q4 | 9.41 Billion JPY | -71.72% |
| 2013 Q3 | 33.26 Billion JPY | 27.59% |
| 2013 Q2 | 26.07 Billion JPY | 17.87% |
| 2013 Q1 | 22.12 Billion JPY | 1339.27% |
| 2012 Q4 | -1.78 Billion JPY | -106.56% |
| 2012 FY | 82.85 Billion JPY | 5.91% |
| 2012 Q1 | 35.48 Billion JPY | 274.2% |
| 2012 Q2 | 21.91 Billion JPY | -38.25% |
| 2012 Q3 | 27.23 Billion JPY | 24.25% |
| 2011 Q1 | 25.14 Billion JPY | 318.55% |
| 2011 Q2 | 26.18 Billion JPY | 4.13% |
| 2011 Q3 | 47.27 Billion JPY | 80.54% |
| 2011 Q4 | -20.37 Billion JPY | -143.1% |
| 2011 FY | 78.23 Billion JPY | 15.64% |
| 2010 Q4 | -11.5 Billion JPY | -132.62% |
| 2010 FY | 67.65 Billion JPY | -44.67% |
| 2010 Q1 | 39.46 Billion JPY | 536.93% |
| 2010 Q2 | 4.42 Billion JPY | -88.79% |
| 2010 Q3 | 35.26 Billion JPY | 697.56% |
| 2009 Q1 | 44.01 Billion JPY | 136.65% |
| 2009 Q2 | 39.47 Billion JPY | -10.3% |
| 2009 Q3 | 32.57 Billion JPY | -17.49% |
| 2009 Q4 | 6.19 Billion JPY | -80.98% |
| 2009 FY | 122.25 Billion JPY | -28.5% |
| 2008 FY | 170.98 Billion JPY | -3.64% |
| 2008 Q4 | 18.59 Billion JPY | -69.74% |
| 2008 Q3 | 61.45 Billion JPY | 34.3% |
| 2008 Q2 | 45.75 Billion JPY | 0.0% |
| 2007 FY | 177.43 Billion JPY | 35.15% |
| 2006 FY | 131.28 Billion JPY | 26.65% |
| 2005 FY | 103.65 Billion JPY | 207.44% |
| 2004 FY | 33.71 Billion JPY | -43.86% |
| 2003 FY | 60.05 Billion JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Kyowa Kirin Co., Ltd. | 81.18 Billion JPY | 79.006% |
| Chugai Pharmaceutical Co., Ltd. | 325.47 Billion JPY | 94.763% |
| Ono Pharmaceutical Co., Ltd. | 127.97 Billion JPY | 86.681% |
| Santen Pharmaceutical Co., Ltd. | 26.64 Billion JPY | 36.022% |
| JCR Pharmaceuticals Co., Ltd. | 5.5 Billion JPY | -209.515% |
| Daiichi Sankyo Company, Limited | 200.73 Billion JPY | 91.509% |
| Otsuka Holdings Co., Ltd. | 121.61 Billion JPY | 85.985% |
| Perseus Proteomics Inc. | -1.1 Billion JPY | 1643.288% |